Lars Lannfelt, MD, PhD, Uppsala University, Uppsala, Sweden, comments on the next steps regarding using lecanemab in the clinical setting for the treatment of Alzheimer’s disease. Positive trial results are expected later this year, and it is anticipated that the monoclonal antibody targeting amyloid beta will be first approved in the US and later in Europe. Prof. Lannfelt believes that all Alzheimer’s disease patients should be able to receive lecanemab and benefit from the treatment; therefore, drug costs shouldn’t be high. This interview took place at the AD/PD™ 2022 Conference in Barcelona, Spain.
